Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression

Journal of Clinical Psychiatry

Volumn 71, Issue 5, 2010, Pages 599-605

  Perlis, Roy H ^a   Adams, David H ^b   Fijal, Bonnie ^c   Sutton, Virginia K ^b,d   Farmen, Mark ^b   Breier, Alan ^b   Houston, John P ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Lilly USA   (United States)

^d i3 Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; GLUCOCORTICOID RECEPTOR; HISTAMINE H1 RECEPTOR; LAMOTRIGINE; MELANOCORTIN 2 RECEPTOR; OLANZAPINE;

ADULT; ALLELE; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDEL MUTATION; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZODIAZEPINES; BIPOLAR DISORDER; DOPAMINE BETA-HYDROXYLASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MELANOCORTIN, TYPE 2; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, GLUCOCORTICOID; RECEPTORS, HISTAMINE H1; TREATMENT OUTCOME; TRIAZINES;

EID: 77952626856     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04632gre     Document Type: Article

References (32)

1. Hirschfeld RM. Bipolar depression: the real challenge. Eur Neuropsychopharmacol. 2004;14(suppl 2):S83-S88.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder (revision). Am J Psychiatry. 2002; 159(suppl):1-50.
3. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in Arch Gen Psychiatry 2004;61(2):176]. Arch Gen Psychiatry. 2003;60(11):1079-1088.
4. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. 0.176/api.ajp.162.7.1351
5. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7): 1025-1033.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
7. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161(5):780-796.
8. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl). 2002; 162(1):18-23.
9. Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2008;23(4):267-274. (Pubitemid 351982663)
10. Spitzer RL, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM-IV-Axis I Disorders, Patient Edition (SCID-P). Washington, DC: American Psychiatric Press; 1996.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
12. Guy W. Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
13. Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55(4):997-1004.
14. Jurinke C, van den Boom D, Cantor CR, et al. Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2002;187: 179-192.
15. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66(6):2621-2624. (Pubitemid 26159101)
16. Lichter JB, Barr CL, Kennedy JL, et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet. 1993;2(6):767-773. (Pubitemid 23197523)
17. Nahmias J, Burley MW, Povey S, et al. A 19 bp deletion polymorphism adjacent to a dinucleotide repeat polymorphism at the human dopamine beta-hydroxylase locus. Hum Mol Genet. 1992;1(4):286.
18. Cavalli-Sforza LL, Bodmer WF. The Genetics of Human Populations. New York, NY: Dover Publications; 1999.
19. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-769. 51
20. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265.
21. Rasmussen K, Benvenga MJ, Bymaster FP, et al. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3- thia-4,9-diaza-benzo[f] azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005;315(3): 1265-1277.
22. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54-60. (Pubitemid 38813406)
23. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord. 2005;86(1):37-45. (Pubitemid 40487958)
24. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 2006;16(6):391-402.
25. Vogel M, Pfeifer S, Schaub RT, et al. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology. 2004;50(4):305-310. (Pubitemid 39482670)
26. Gelernter J, Yu Y, Weiss R, et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet. 2006;15(24):3498-3507. (Pubitemid 44884117)
27. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23(6):540-545.
28. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry. 2000;177:390-395.
29. Webster MJ, Knable MB, O'Grady J, et al. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry. 2002;7(9):985-994. (Pubitemid 35333054)
30. Spiliotaki M, Salpeas V, Malitas P, et al. Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients. Psychoneuroendocrinology. 2006;31(6):748-760. (Pubitemid 43732410)
31. Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol. 2007;27(5):520-523. (Pubitemid 47415058)
32. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437(7063):1299-1320.